The bradykinin-forming enzyme kallikrein-1 is expressed in the heart. To examine whether contractile performance and sarcoplasmic reticulum Ca 2+ transport of the diabetic heart can be rescued by targeting the kallikrein-kinin system, we studied left ventricular function and sarcoplasmic reticular Ca 2+ uptake after induction of streptozotocin-induced diabetes mellitus in transgenic rats expressing the human tissue kallikrein-1 gene. Six weeks after a single injection of either streptozotocin (70 mg/kg ip) or vehicle, left ventricular performance was determined using a Millar-Tip catheter system. The Ca 2+ -transporting activity of reticulum-derived membrane vesicles was determined in left ventricular homogenates as oxalate-supported 45 
Key words: bradykinin • cardiomyopathy • diabetes mellitus • phospholamban phosphorylation solated diastolic dysfunction is an early manifestation of diabetic cardiomyopathy (1) . Clinical and experimental evidence supports the concept that this is associated with abnormal cellular Ca 2+ handling due to impairment of Ca 2+ transport processes in cardiac membranes (2) (3) (4) (5) . In particular, the function of the Ca 2+ pump of the sarcoplasmic reticulum (SR) SERCA2a is affected (3) (4) (5) ; however, this can be reversed by insulin substitution therapy (4) . It is, however, not known whether other peptide hormones facilitating cardiac glucose uptake insulin independently, such as kinins (6) , could rescue contractile function and SR Ca 2+ handling. It is also unknown, whether reported changes of the cardiac kallikrein-kinin system (KKS) in diabetic animals such as reduced endogenous kininogen and kallikrein (KLK) levels and/or alterations in the activation of the cardiac tissue KLK (7-9) may contribute to deteriorations of SR Ca 2+ handling, and hence, contractile dysfunction of the diabetic heart. Because alterations of both diastolic dysfunction and SERCA2a expression have been reported to be blunted by increasing the bradykinin (BK) B 2 receptor signaling in experimental heart failure (10), we investigated whether interventions increasing the activity of the cardiac KKS are beneficial for both contractile performance and SR Ca 2+ handling in diabetic cardiopathy. In this context, we analyzed the SR Ca 2+ cycling protein SERCA2a, its endogenous modulator phospholamban (PLB), left ventricular (LV) performance, and the cardiac expression of several KKS components in diabetic wild-type (WT) and transgenic rats (TGR) that express a metallothionein promoter-controlled human tissue kallikrein-1 (hKLK1) gene in the heart, kidney, brain, and lung at both the mRNA and protein level (11) .
MATERIALS AND METHODS

Animals and experimental design
The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996) and has been approved by the local ethics committee "Landesamt für Arbeitsschutz, Gesundheitsschutz und technische Sicherheit Berlin" (Permission number: G 0204/99).
Diabetes mellitus was induced in 300-330 g male Sprague-Dawley WT rats and homozygous TGR(hKLK1) (n=10 each) by a single injection of STZ (70 mg/kg ip) dissolved in 0.1 M sodium citrate, pH 4.5, as described previously (9) . Hyperglycaemia was confirmed 48 h later using a reflectance meter (Acutrend, Boehringer, Mannheim, Germany) as well as at the end of the study. Vehicle-treated WT and TGR(hKLK1) served as controls (n=10 each). An additional group of diabetic TGR(hKLK1) (n=10) was treated with 0.5 mg/kg/day of the B 2 receptor antagonist icatibant (Hoe 140) between 4 days after STZ injection and the end of the study using osmotic mini-pumps (Alzet: model 2ML4 for the first 4 wk, model 2002 for the last 2 wk of the study design). After 6 wk, ventilated, open-chest rats were subjected to LV catheterization under ketamin/xylazin anesthesia using the technique reported previously (9, 12) . The developed LV pressure (LVP) and the peak rate of rise in LV pressure (dP/dt max ) characterizing systolic performance as well as the maximum rate of LV pressure decay (dP/dt min ), a hemodynamic parameter for LV relaxation, were determined. Since early relaxation is mainly controlled by SR Ca 2+ re-uptake, the time constant of isovolumic pressure decline (tau) and pressure half-time (PHT) I were also analyzed. Thereafter, the hearts were excised, shock-frozen in liquid N 2 , and stored at -80°C until used for biochemical and molecularbiological analysis.
Determination of SR Ca 2+ uptake
Tissue homogenates were prepared from 50 mg LV tissue at 4°C under stringent phosphoprotein protection conditions (5) . Protein was determined by Lowry's method. Oxalate-supported SR Ca 2+ uptake was measured in LV homogenates at 37°C using a vacuum filtration technique as described previously (5) . Thapsigargin and the ionophore A23187 at 10 µmol/l prevented Ca 2+ uptake completely. Calculations of free Ca 2+ concentration, EC 50 and V max values were done as described previously (5) .
Western blot analysis
Homogenate proteins were subjected to electrophoresis according to the Swank and Munkres protocol as described earlier (5) . Protein transfer to PVDF membranes (Roche, Mannheim, Germany), membrane blocking, and detection and quantification of SERCA2 and PLB with specific antibodies were performed as reported previously (5) . For site specific phosphorylation of PLB, blots were probed with the site-specific phosphoserine(PSer 16 )-and phosphothreonine(PThr
17
)-PLB antibodies (Badrilla, Leeds, UK). Immunoreactive SERCA2, PLB, PSer 16 -PLB, and PThr 17 -PLB were visualized using SuperSignal® West Pico chemiluminescent substrates (Pierce, Rockford, IL) and Kodak R Medical Imaging film. Exposure time was 0.5-2 min. Quantification of the immunoreactive bands was performed after densitometric scanning as described previously (5) .
RNase protection assay
Cardiac steady-state of human KLK, rat KLK, BK B 1 , and B 2 receptor as well as of GAPDH mRNA levels were determined using 25 µg RNA in RNase-protection assays (RPA) as described previously (13) . Quantification of the respective mRNA signal intensity of the target bands was performed using a FUJIX BAS2000 Phosphoimager System (Raytest, Straubenhardt, Germany). Specific mRNA signals were normalized to that of GAPDH mRNA.
Determination of coronary BK outflow
Coronary BK outflow was determined in Langendorff mode buffer-perfused isolated hearts of WT and TGR(hKLK1) (n=7 each) as recently described (14) . Briefly, hearts were perfused via the aorta at a constant perfusion pressure of 60 mmHg using a modified Krebs-Henseleit solution. The coronary effluent was collected in 5 ml fractions and was immediately supplemented with 1% trifluoroacetic acid. Kinins were adsorbed to phenyl-silica (Isolute SPE, International Sorbent Technology, Mid Glamorgan, UK) and eluted in 50% acetonitrile and 0.1% trifluoroacetic acid. After lyophilization and reconstitution of the samples in radioimmunoassay buffer, BK was quantitated by a specific radioimmunoassay as described previously (15) . The antiserum displayed a 36% cross-reactivity to T-kinin and had no affinity to smaller kinin fragments such as [1] [2] [3] [4] [5] [6] [7] [8] -, [1] [2] [3] [4] [5] [6] [7] -, or [1] [2] [3] [4] [5] -BK. The detection limit of the assay, based on the amount of BK that produced at least 10% tracer displacement, was 1 pg per tube. Data are given without consideration to extraction recovery which typically amounted to 85%. Intra-and interassay variability was 9 and 11%, respectively.
BK-induced phosphorylation in cardiomyocyte cultures
Primary neonatal cardiomyocyte cultures were prepared from ventricular tissue of 1-to 3-dayold Spague-Dawley rats and grown in serum-supplemented CMRL 1415-ATM medium (1.5×10 6 cells per well of a 6-well culture plate) as described earlier (16) . After 4 days in culture, cells were incubated in serum-free growth medium (3 ml/well) at 30°C for 3 h and then exposed to 10 −7 M BK for 0.25, 0.5, 1, 2, 5, and 10 min. BK-mediated reactions were terminated by addition of 1 ml 20% ice-cold trichloroacetic acid (TCA). After removal of the fluid from the wells and three successive washes with 1 ml ice-cold 5% TCA each, denatured cell material was collected by differential centrifugation at 4°C. 
Statistical evaluation
Data are means ± SE if not otherwise indicated. Statistical analysis was performed using either ANOVA followed by Bonferroni's post hoc test or Kruskal-Wallis one way ANOVA followed by Dunn's test for multiple comparisons. For group-to-group comparison of Western blotting data, the Mann-Whitney rank sum test was used. Differences were considered significant at the level of P < 0.05.
RESULTS
General characteristics and LV function
The heart-to-body-weight ratios and blood glucose levels were similar in nondiabetic WT and TGR(hKLK1). Diabetic WT and TGR(hKLK1) displayed severe hyperglycemia and ~50% less body weight. Because of a lesser loss of heart weight, the heart-to-body-weight ratio of diabetic TGR(hKLK1) and diabetic WT was significantly increased but was not different between them (Table 1) . Heart rate and LV function characteristics were similar in nondiabetic WT and TGR(hKLK1), indicating no adverse effect of tissue hKLK1 gene expression under euglycemic conditions. LV dysfunction was observed in diabetic WT. Thus, LVP and dP/dt max reached only 58 and 44%, respectively, of the nondiabetic WT values. This was paralleled by a significantly slowed early LV diastolic pressure decline as indicated by altered values of dP/dt min (-58%), tau (+43%), and PHT (+43%) as compared with nondiabetic WT. In diabetic TGR(hKLK1), LV dysfunction was attenuated. The LVP, dP/dt max , and dP/dt min values were +34, +47, and +66% higher, respectively, if compared with diabetic WT (P<0.05). Furthermore, the diastolic time parameters tau and PHT of diabetic TGR(hKLK1) did not differ significantly from those of nondiabetic WT. Treatment of diabetic TGR(hKLK1) with icatibant led to a further increase of the heart-to-body-weight ratio and, except for LVP, to a significant attenuation of the transgenerelated improvement of the diastolic dysfunction.
SR Ca 2+ uptake in vitro
To examine whether contractile dysfunction was linked to altered reticular Ca 2+ transport 45 Ca 2+ uptake into SR vesicles was determined in LV homogenates. Figure 1A and B shows the depend-encies of SR Ca 2+ uptake for the experimental groups. In diabetic WT, rate values of Ca 2+ uptake were markedly decreased at all tested Ca 2+ concentrations if compared with nondiabetic WT (Fig. 1A) . The respective V max value of Ca 2+ uptake was 61% of that in nondiabetic WT (Table  2) . By contrast, diabetic TGR(hKLK1) exhibited no significant decrease in Ca 2+ uptake if compared with nondiabetic TGR ( Fig. 1B ; Table 2 ). Moreover, the V max value of diabetic TGR was 42% higher as compared with diabetic WT. This protection was completely abolished if diabetic TGR were chronically treated with Hoe 140 (Fig. 1B) , indicating involvement of a B 2 receptormediated mechanism. Kinetic analysis of Ca 2+ uptake revealed no significant differences in the EC 50 values between the groups (Table 2) .
SR proteins and phosphorylation of PLB
To study the abundance of involved SR proteins, Western blot analysis was performed using SERCA2-and PLB-specific antibodies (Fig. 2) . We did not observe significant differences between the experimental groups with respect to SERCA2 and PLB levels ( To test whether BK is principally capable to induce phosphorylation of PLB, additional experiments were performed using neonatal rat cardiomyocytes in culture as a different model. There occurred a transient increase in PLB phosphorylation at Thr 17 in response to BK. By contrast, the status of the PKA-specific Ser 16 -phosphorylation site was not altered by this peptide (Fig. 5) .
Coronary BK outflow and cardiac mRNA of KKS components
BK outflow of TGR(hKLK1) was 3.48-fold increased compared of WT rats (0.94±0.18 vs. 0.24±0.05 pg/ml; P<0.01). As summarized in Table 3 , B 1 and B 2 receptor mRNAs were increased 4-and 2.8-fold in LV of diabetic WT (P<0.05 vs. nondiabetic WT). The respective values of diabetic TGR were 27.7-and 5.4-fold increased as compared with nondiabetic TGR (P<0.05). As anticipated, hKLK mRNA was expressed in TGR(hKLK1) only. The expression level was not altered by the metabolic status. However, rat KLK expression was below the detection level when 25 µg total RNA were used.
DISCUSSION
In this study, we used TGR with expression of hKLK to investigate the influence of a chronically activated tissue KLK system on contractile performance and SR Ca 2+ handling in STZ-induced diabetic cardiomyopathy. Our findings indicate that 1) in diabetic cardiomyopathy, targeting the KLK expression was beneficial for defective systolic and diastolic performance; 2) diabetic TGR(hKLK1), in contrast to diabetic WT, showed no significant impairment of the SR Ca 2+ transport activity; 3) improved SR Ca 2+ uptake in diabetic TGR(hKLK1) was linked to increased phosphorylation of PLB at the CaM kinase-specific residue Thr 17 ; and 4) these transgene-related beneficial effects were at least partly abolished by treatment with the BK B 2 receptor antagonist icatibant. The findings suggest that expression of a tissue KLK transgene can protect the rat heart, at least in part, against diabetes-specific contractile disturbances due to rescued SR Ca 2+ handling. Thereby, a B 2 receptor-mediated process leading to enhanced phosphorylation of PLB at Thr 17 is involved.
Cardiac KKS and heart function
The functional status of the cardiac KKS is critical for heart function. Pharmacological interventions and gene targeting leading to kinin potentiation are known to attenuate cardiac dysfunction and damage under various pathological conditions (12, 17, 18) . In TGR(hKLK1), cardioprotective effects arising from hKLK1 expression have been found under different experimental conditions, including cardiac ischemia and isoproteronol-induced stress (11, 19, 20) . Most interestingly, an improvement of the deranged extracellular matrix regulation was recently observed in diabetic TGR(hKLK1) (20) . Kinins are of special interest in diabetic cardiopathy. In particular, their potential NO-related free radical scavenging properties, endothelium-dependent vasodilatating and antifibrotic action, as well as their stimulating effect on glucose uptake are thought to be beneficial in diabetes (6, 18, 19, 21) .
However, in experimental diabetic cardiopathy, the status of cardiac KKS is affected as indicated by increased levels of mRNAs coded by both BK receptor genes (9, 13) and by reduced mRNA and immunoreactive levels of cardiac KLK (8) . However, the later had no effect of cardiac BK levels, since coronary BK outflow did not differ compared with normoglycemic controls (9, 14) . In diabetic TGR(hKLK1), we found a much stronger increase in the B 1 and B 2 receptor mRNA levels than in diabetic WT. These findings and the increased B 1 and B 2 receptor mRNA levels in nondiabetic TGR may point out the existence of a TGR(hKLK1)-specific compensatory mechanism that is linked to an increased BK receptor turnover under conditions of an activated KKS. Furthermore, a heart-specific increase of the KKS activity in TGR(hKLK1) is supported by the finding of a 3.5-fold higher coronary BK outflow in the transgenic animals as compared with WT.
Since Fujii et al. (10) reported on a beneficial effect of BK an LV diastolic function and SR Ca
2+
ATPase mRNA expression in a tachycardia-induced dog heart failure model, we examined whether a potentiated KKS in TGR(hKLK1) is capable to improve diastolic dysfunction under diabetic conditions. In this study, we found marked systolic and diastolic dysfunction in diabetic WT. In fact, significantly impaired LVP, dP/dt max, dP/dt min , tau, and PHT values confirm earlier reports on WT diabetic rats (22, 23) . By contrast, diabetes-induced contractile dysfunction was markedly attenuated in hKLK1 expressers. In particular, the SR Ca 2+ ATPase-controlled early relaxation process was markedly faster than in diabetic WT as indicated by the observed changes in tau and PHT.
Cardiac SR Ca 2+ uptake in diabetic TGR(hKLK1)
Slowed relaxation is a typical sign of diastolic dysfunction in the diabetic myocardium. It appears to be largely due to defective Ca 2+ re-uptake by the SR (3-5), which plays a central role for altered cellular Ca 2+ cycling (24, 25) that is linked to impaired relaxation and contraction (5) . In agreement with these previous results, we found a marked reduction of the SERCA2a-mediated SR Ca 2+ uptake in diabetic WT. By contrast, SR Ca 2+ transport was rescued in STZ-diabetic TGR(hKLK1). Thus, Ca 2+ uptake rates of diabetic TGR determined at different Ca 2+ concentrations did not differ significantly from values of nondiabetic TGR(hKLK1) and WT (see Fig. 1 and Table 2 ). The beneficial effect in transgenic hKLK1 expressers occurred under conditions of persisting hyperglycaemia and insulin deficiency, and it was completely abolished by treatment of diabetic TGR(hKLK1) with icatibant. This strongly suggests that rescue of the cardiac SR Ca 2+ transport function in diabetic TGR(hKLK1) occurs via a BK B 2 receptor-mediated mechanism. Although we cannot exclude a possible involvement of the BK B 1 -receptor under the specific conditions, our results are in line with the recently reported B 2 receptor-dependent improvement of diastolic dysfunction and increase in SERCA2a mRNA in tachycardia-induced heart failure (10). In summary, our findings demonstrate that a permanent KKS activation due to KLK gene targeting is useful to prevent diabetes-caused alterations of the cardiac SR Ca 2+ transport.
Possible mechanism of rescued SR Ca 2+ transport
The interactions of the SR Ca 2+ ATPase with its inhibitory protein PLB control SR Ca 2+ uptake and thus the process of relaxation and contraction (26, 27). The abundance of SERCA2 and PLB molecules in the SR membranes and, hence, the SERCA2-to-PLB-ratio is critical in the control of cardiac contraction and relaxation (26, 27). Because we did not find obvious differences in the cardiac levels of SERCA2 and PLB between the experimental groups, changes in the abundance of these two proteins cannot be the underlying mechanism for rescued Ca 2+ transport in diabetic TGR(hKLK1). On the other hand, it is known that interactions of the SR Ca 2+ ATPase with PLB and thus the SR Ca 2+ transport activity are dependent on the phosphorylation status of PLB (26, 27). Western blot analyses with site-specific antibodies against PSer 16 -PLB (28) revealed low PLB phosphorylation at the protein kinase A-specific site and did not show significant differences among the experimental groups (data not shown). Obviously, this also excludes a contribution of protein kinase A-catalyzed PLB phosphorylation as an underlying mechanism for the improved SR Ca 2+ uptake in diabetic TGR(hKLK1). This conclusion is also supported by the finding of similar apparent affinities of the Ca 2+ ATPase for Ca
2+
. Lowering this affinity by phosphorylation of PLB at Ser 16 is known to accelerate SR Ca 2+ uptake at low Ca 2+ concentrations (27, 29). In contrast, the observed increase in net phosphorylation of PLB at the CaM kinase-specific residue Thr 17 in diabetic TGR and the complete prevention of this increase by treatment with Hoe 140 strongly suggests involvement of a B 2 receptor-mediated process. It was most likely the enhanced net phosphorylation of PLB at Thr 17 that caused the complete restoration of the depressed SR Ca 2+ transport activity in hearts of diabetic TGR(hKLK1). The observed linear relationship between the PThr 17 -PLB levels and the respective SR Ca 2+ uptake rates of diabetic animals (see Fig. 4 ) supports this conclusion. In diabetic TGR(hKLK1), increased Thr 17 -PLB phosphorylation was associated with an increase in V max of the Ca 2+ uptake reaction but not a lowering in the apparent affinity for Ca 2+ (see Table 2 ).
This is contradictory to previous findings in nondiabetic myocardium (29) and genetically engineered noncardiac cells co-expressing SERCA2a and PLB (30) showing that CaM kinase II (CaMKII)-dependent PLB phosphorylation at Thr 17 produces a lowering of Km(Ca). However, our findings agree with less generally accepted reports that suggest an increased V max due to CaMKII phosphorylation of PLB with less (or no) effect on the apparent affinity for Ca 2+ -release channels (40). For the latter, reduced expression has been reported for the STZdiabetic rat heart (37). It is, however, not known whether IP 3 R expression is altered in addition. It is noteworthy in this context that increased expression of IP 3 R in human end-stage heart failure is associated with opposite changes in RYR mRNA levels (41). Although the various components of the putative BK→IP 3 →Ca 2+ release→CaMK signaling pathway have not been directly studied in this work, we postulate that the observed increased phosphorylation of PLB at Thr 17 in diabetic TGR(hKLK1) was due to activation of this pathway. The notion that BK is principally capable to alter the phosphorylation status of PLB at the CaMK-specific site is supported by our finding of a transiently increased PLB phosphorylation at Thr 17 in cultured neonatal rat cardiomyocytes that were exposed to 10 −7 M BK. It should not be dismissed that the activation of CaMKII via the above mentioned signaling pathway could also result in phosphorylation of other Ca 2+ cycling proteins, such as L-type Ca 2+ channel, RYR, and SERCA2a (42), the phosphorylation of which was not studied in this work. Furthermore, phosphorylation of the Ca 2+ ATPase by CaMKII has been reported to be associated with an increase in V max rather than changes in the apparent affinity for Ca 2+ (43, 44). We cannot exclude that this possible mechanism, which has been challenged by other investigators (30, 45), contributed to the observed increase in SR Ca 2+ uptake in diabetic TGR(hKLK1).
As mentioned above kinins can improve coronary perfusion, myocardial glucose uptake and extracellular matrix remodeling. It is therefore conceivable that apart from the suggested direct kinin-mediated action on SR Ca 2+ handling, additional indirect kinin-mediated cardioprotective effects might have also contributed to improved SR Ca 2+ handling and preserved LV function under STZ-induced diabetic conditions. In summary, the results of our study demonstrate that a potentiated KKS is capable to counteract, at least partially, the development of contractile dysfunction in STZ-induced diabetes. This improvement was obviously linked to rescued SR Ca 
